Work

Tolvaptan, hyponatremia, and heart failure

Year: 2011

Type: article

Abstract: Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan inhibits the binding of arginine vasopressin to the V(2) receptors on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion of water. This article reviews the accumulated experience with tolvaptan and all the major clinical trials that were conducted to study its safety and efficacy and concludes by summarizing clinicians' views of its current application in clinical practice.

Source: International Journal of Nephrology and Renovascular Disease

DOI: 10.2147/ijnrd.s7032

Authors: Jalal Ghali, Hammam Zmily, Suleiman Daifallah

Institutions: Detroit Medical Center, Harper University Hospital, Wayne State University, John D. Dingell VA Medical Center

Language: English

Topic: Electrolyte and hormonal disorders

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,320